Insider · CIK 0001871145
Jason O'Byrne
cfoofficer
Files at VIR (Vir Biotechnology, Inc.), OLMA (Olema Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | OLMA Olema Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | 40 d ago |
| Nov 15, 2024 | VIR Vir Biotechnology, Inc. | AGrant or award Common Stock10b5-1 | +75,000 | $0.00 | $0 | 75,000 | Nov 18, 2024 |
| Nov 15, 2024 | VIR Vir Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +150,000 | $0.00 | $0 | 150,000 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.